NIBRT Opens seven research laboratories and training suites for manufacturing complex medicines

According to the reports, The National Institute for Bioprocessing Research and Training has officially launched a new advanced therapies facility at its site in Dublin. 

The launch of this training facility aims to increase the capacity and capability to conduct research related to manufacturing and training in advanced therapeutics. 

Advanced Therapies is an umbrella term that covers innovative biological medicines such as cell therapies, gene therapies, mRNA and DNA-based therapies, and other novel biomedicine and vaccines. 

This new facility is large enough to accommodate twenty-five new researchers and training staff and will serve both new and existing NIBRT clients. NIBRT offers solutions to challenges regarding manufacturing and training to produce highly innovative and complex medicines. 

The Irish Government supports this project through IDA Ireland by funding €21 M, which incorporates 1,800 square meters of space, which is used to construct seven research laboratories and state-of-the-art training suites. 

The facility also houses a €6.5m SFI/IDA co-funded research facility known as CONCEPT, assigned to the early-stage development of biologic therapies. 

The CEO of NIBRT, Darrin Morrissey, says, “The role of NIBRT is to help the growth and development of the biopharma manufacturing sector in Ireland by providing cutting edge training and research solutions.

"NIBRT intends to further enhance our current capability by becoming a leader in the pioneering and fast-evolving area of advanced therapies and vaccines.

"It is an immensely exciting time for NIBRT. With this expansion, we expect to deliver training for many more potential and newly-hired biopharma staff, as well as considerable growth in our research activities.

"This has the potential to rapidly enhance Ireland’s standing as a location of choice for advanced therapy and vaccine manufacturing.”

The CEO of IDA Ireland, Michael Lohan, congratulated NIBRT by saying: “Ireland’s thriving biopharma sector, coupled with its abundant talent pool and dynamic business ecosystem, underscores our appeal as a premier destination for this investment.

"Congratulations to NIBRT on the opening of their new facility, which further strengthens Ireland’s position as a global leader in biopharmaceutical innovation.”